TY  - JOUR
AU  - Stocker, Hannah
AU  - Beyer, Léon
AU  - Trares, Kira
AU  - Perna, Laura
AU  - Rujescu, Dan
AU  - Holleczek, Bernd
AU  - Beyreuther, Konrad
AU  - Gerwert, Klaus
AU  - Schöttker, Ben
AU  - Brenner, Hermann
TI  - Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers.
JO  - JAMA network open
VL  - 6
IS  - 1
SN  - 2574-3805
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DKFZ-2023-00174
SP  - e2252387 -
PY  - 2023
N1  - #EA:C070#LA:C070#
AB  - Previous research has suggested an association of kidney function with risk of Alzheimer disease (AD) or other dementias and dementia-related blood biomarkers, but a distinct association remains unclear.To evaluate the association of kidney function with risk of diagnosis of incident AD or dementia within 17 years and with the blood biomarkers neurofilament light (NfL), phosphorylated tau181 (p-tau181), and glial fibrillary acidic protein (GFAP).In this prospective, population-based cohort study and nested case-control study, 9940 participants in Germany were enrolled between 2000 and 2002 by their general practitioners and followed up for up to 17 years. Participants were included if information on dementia status and creatinine/cystatin C measurements were available. A subsample of participants additionally had measurements of NfL, p-tau181, and GFAP obtained from blood samples. Statistical analysis was performed from January 3 to November 25, 2022.Impaired kidney function, based on estimated glomerular filtration rate less than 60 mL/min/1.73 m2 according to the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation.All-cause dementia, AD, and vascular dementia diagnosis, as well as log-transformed levels of NfL, p-tau181, and GFAP in blood.Of 6256 participants (3402 women [54.4
LB  - PUB:(DE-HGF)16
C6  - pmid:36692879
DO  - DOI:10.1001/jamanetworkopen.2022.52387
UR  - https://inrepo02.dkfz.de/record/212457
ER  -